Longjin Pharmaceutical(SZ:002750) Tong Hua Shun Cai Bao·2025-04-24 16:36Financial Performance - The basic earnings per share for 2024 is -0.1035 yuan, showing a 41.56% improvement compared to -0.1771 yuan in 2023 [1] - The net profit for 2024 is -0.41 billion yuan, which is a 42.25% increase from -0.71 billion yuan in 2023 [1] - The operating revenue for 2024 is 0.66 billion yuan, reflecting a decrease of 24.14% from 0.87 billion yuan in 2023 [1] - The return on equity for 2024 is -8.44%, an improvement of 34.88% from -12.96% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 23,725.74 million shares, accounting for 59.51% of the circulating shares, with a change of 343.80 million shares from the previous period [1] - The largest shareholder, Kunming Qunxing Investment Co., Ltd., holds 15,778.23 million shares, representing 39.57% of the total share capital, with no change [2] - New entrants among the top shareholders include Xu Jiawei with 333.02 million shares and Wang Qiyu with 251.00 million shares [2] Dividend Distribution - No specific dividend distribution plan is mentioned in the provided data [3]